BRAG2 Activators
BRAG2 Activators encompass a set of chemical compounds specifically tailored to augment the functional activity of BRAG2 through distinct signaling mechanisms. Forskolin, by raising intracellular levels of cAMP, indirectly enhances BRAG2's GEF activity by activating PKA, which may phosphorylate substrates that positively regulate BRAG2, leading to an upsurge in G protein signaling. Analogously, 8-Bromo-cAMP, a stable cAMP analog, and IBMX, a broad-spectrum phosphodiesterase inhibitor, elevate PKA activity, potentially enhancing the GEF function of BRAG2 by affecting the phosphorylation state of its interacting partners. Epigallocatechin gallate (EGCG) acts as a kinase inhibitor, possibly decreasing competitive phosphorylation events that would otherwise negatively affect BRAG2 function, thus promoting its activity. Furthermore, LY294002 and U0126, inhibitors of PI3K and MEK respectively, modulate downstream signaling processes, which may contribute to an upregulation of BRAG2's GEF activity by altering intracellular signaling dynamics that favor BRAG2 activation.
In addition to these, PMA, a PKC activator, and Gö 6983, a PKC inhibitor, both influence the phosphorylation landscape of intracellular proteins that could modulate BRAG2 activity, albeit through different mechanisms. Ionomycin and A23187, calcium ionophores, induce an increase in intracellular calcium levels, which may trigger calcium-dependent signaling cascades that enhance BRAG2's activation. Sphingosine-1-phosphate operates through its receptors to activate G proteins, potentially working in tandem with BRAG2's GEF function. Lastly, NF449 selectively inhibits the Gsα subunit, which might reduce competitive GTPase activity, indirectly favoring the G protein signaling pathways that BRAG2 is poised to activate. Collectively, these BRAG2 Activators work through a multifaceted network of cellular signaling events, converging on the augmentation of BRAG2's intrinsic GEF activity without necessitating an upregulation of its expression or direct activation.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $78.00 $153.00 $740.00 $1413.00 $2091.00 | 73 | |
Forskolin acts by directly stimulating adenylyl cyclase, thereby increasing intracellular cAMP levels. This elevation of cAMP can activate PKA, which may phosphorylate targets that positively regulate the GEF activity of BRAG2, enhancing its activation of G protein signaling pathways. | ||||||
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $41.00 $132.00 $214.00 $500.00 $948.00 | 119 | |
PMA is a diacylglycerol analog that activates protein kinase C (PKC). PKC activation can lead to phosphorylation of proteins that interact with BRAG2, potentially increasing its GEF activity toward its target G proteins. | ||||||
Ionomycin, free acid | 56092-81-0 | sc-263405 sc-263405A | 1 mg 5 mg | $96.00 $264.00 | 2 | |
Ionomycin is a calcium ionophore that increases intracellular calcium levels. Elevated calcium can activate calmodulin and other calcium-binding proteins, which may interact with BRAG2, enhancing its GEF function. | ||||||
8-Bromo-cAMP | 76939-46-3 | sc-201564 sc-201564A | 10 mg 50 mg | $126.00 $328.00 | 30 | |
8-Bromo-cAMP is a cell-permeable cAMP analog. It activates PKA, leading to phosphorylation of proteins that could enhance the GEF function of BRAG2 by modulating its interaction with G proteins. | ||||||
(−)-Epigallocatechin Gallate | 989-51-5 | sc-200802 sc-200802A sc-200802B sc-200802C sc-200802D sc-200802E | 10 mg 50 mg 100 mg 500 mg 1 g 10 g | $43.00 $73.00 $126.00 $243.00 $530.00 $1259.00 | 11 | |
EGCG is known to inhibit certain protein kinases, potentially altering phosphorylation states of proteins that regulate BRAG2 activity or its binding partners, thereby enhancing BRAG2-mediated G protein activation. | ||||||
D-erythro-Sphingosine-1-phosphate | 26993-30-6 | sc-201383 sc-201383D sc-201383A sc-201383B sc-201383C | 1 mg 2 mg 5 mg 10 mg 25 mg | $165.00 $322.00 $570.00 $907.00 $1727.00 | 7 | |
Sphingosine-1-phosphate activates sphingosine-1-phosphate receptors, which can lead to downstream activation of G proteins that might work synergistically with BRAG2's GEF activity. | ||||||
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $260.00 $350.00 $500.00 | 34 | |
IBMX is a non-specific inhibitor of phosphodiesterases, leading to increased cAMP levels and subsequent activation of PKA, which can phosphorylate proteins that modulate BRAG2 GEF activity. | ||||||
Gö 6983 | 133053-19-7 | sc-203432 sc-203432A sc-203432B | 1 mg 5 mg 10 mg | $105.00 $299.00 $474.00 | 15 | |
Gö 6983 is a PKC inhibitor, which can prevent PKC from phosphorylating proteins that negatively regulate BRAG2, thereby potentially enhancing BRAG2's activity. | ||||||
NF449 | 627034-85-9 | sc-478179 sc-478179A sc-478179B | 10 mg 25 mg 100 mg | $203.00 $469.00 $1509.00 | 1 | |
NF449 is a potent and selective inhibitor of Gsα subunit of G proteins. By inhibiting Gsα, NF449 may reduce competitive GTPase activity, potentially favoring BRAG2-mediated G protein signaling. | ||||||
A23187 | 52665-69-7 | sc-3591 sc-3591B sc-3591A sc-3591C | 1 mg 5 mg 10 mg 25 mg | $55.00 $131.00 $203.00 $317.00 | 23 | |
A23187 is an ionophore that selectively transports calcium across biological membranes. Increased intracellular calcium can activate signaling pathways that may enhance the GEF activity of BRAG2. | ||||||